Phaseline

Targets › SLC30A10

SLC30A10 (Calcium/manganese antiporter SLC30A10): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jul 2030.

Calcium:manganese antiporter of the plasma membrane mediating the efflux of intracellular manganese coupled to an active extracellular calcium exchange. Required for intracellular manganese homeostasis, an essential cation for the function of several enzymes, including some crucially important for the metabolism of neurotransmitters and other neuronal metabolic pathways. (UniProt, Q6XR72)

Open in Phaseline: the race on SLC30A10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Neurological Disorders and Stroke (NINDS)Mangafodipir
Manganese-based contrast agent for MRI
SLC30A10Phase 1EpilepsyJul 2030

Conditions

Epilepsy (1)

Modalities

small molecule (1)

Companies

National Institute of Neurological Disorders and Stroke (NINDS) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.